The prevalence of HBV in the city of Zawia, Libya

Paper Details

Research Paper 01/02/2020
Views (440) Download (22)
current_issue_feature_image
publication_file

The prevalence of HBV in the city of Zawia, Libya

Abd Alla A Mohamed, Altayeb Elazomi, Elhadi Araibi, Fawzia Shawesh, Taher M Abdelhameed, Wayel A Almrabet, Alsadig EM Alghoull, Ali Ysef Alkhboli
Int. J. Micro. Myco.11( 2), 1-6, February 2020.
Certificate: IJMM 2020 [Generate Certificate]

Abstract

Hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide. It is development of end-stage liver disease and carcinoma. Studies have shown that patients infected with HBV may respond to different antiviral therapy and information about HBV prevalence is very important in helping physicians to provide better treatments. The aim of the work was to study the prevalence of HBV in the city of Zawia- Libya. 348 samples were analyzed using ELISA test at Zawia Reference Laboratory, the study showed that out of 348 patients, males were 237 and females were 111, their ages ranged from 14 to 83 years, and they were distributed into four age groups. The percentage in first group (4.88%), in the second group (62.64%), in the third group (28.44%), and in the fourth group (4.02%). The non-Libyan patients represent about 28% of the infections and most of the neighboring countries. The vast majority of HBV infections were in the age range of 21 – 60 years (91.08%), which are more subjected to risk factors since they are at the working age. Furthermore, people older than 60 years represent only about 4.02%, suggesting that HBV infections were less common earlier or infected patients did not survive to reach age older than 60 years. The data also showed that both males and females are equally vulnerable to the infection and most of the neighbor countries are represented in these patients.

VIEWS 54

Chen T. 2019. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia–Pacific region. Hepatol. Int. doi:10.1007/s12072-019-09992-x.

Cho EJ. 2017. Current status and strategies for hepatitis B control in Korea. Clinical and molecular hepatology vol 23, 205-211

Davis K. 2018. Hepatitis B: Causes, symptoms, and treatment. https://www.medicalnewstoday. com/articles/306288.php#what-is-hepatitis-b

Ezzikouri S, Pineau P, Benjelloun S. 2013. Hepatitis B virus in the Maghreb Region: From epidemiology to prospective research. Liver Int 33, 811-819

Gerlich WH. 2013. Medical Virology of Hepatitis B: How it began and where we are now. Virology Journal vol 10

Huang P. 2015. Seroepidemiology of hepatitis B virus infection and impact of vaccination. World J. Gastroenterol 21, 7842-7850

Karayiannis P. 2017. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatology International vol 11, 500-508

Khan F. 2011. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J 8,

Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. 2019. Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention. Infectious Disease Clinics of North America vol 33, 1045-1062

Madour A, Alkout A, Vanin S. 2013. First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya. East. Mediterr. Heal. J 19, 990-994

National Health Service. 2019. Hepatitis B – Symptoms – NHS. https://www.nhs.uk/conditions /hepatitis-b/symptoms/

Nelson NP, Easterbrook PJ, McMahon BJ. 2016. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clinics in Liver Disease vol 20, 607-628

Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212-2219

Schillie S. 2018. Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices. MMWR Recomm. Reports 67, 1-31

Trépo C, Chan HLY, Lok A. 2014. Hepatitis B virus infection. The Lancet vol 384, 2053-2063

Vyas AK. 2019. Maternal Immunity Influences Vertical Transmission of Hepatitis B to Newborns. Hepatol. Commun 3, 795-811

WHO. 2016. Immunization country profile. Who 1 doi: 10.1016/ j.jstrokecerebrovasdis. 2013. 09. 011.

Wright CM, Boudarène L, Ha NT, Wu O, Hawkins N. 2018. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. BMC Public Health vol. 18

Wu J, Han M, Li J, Yang X, Yang D. 2020. Immunopathogenesis of HBV Infection. Adv. Exp. Med. Biol 1179, 71-107.

Xie Q. 2015. ACEI/ARB underused in patients with type 2 diabetes in Chinese population (CCMR-3B study). PLoS One 10.